These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26357866)

  • 21. No Additional Effect of DPP-4 Inhibitor on Preventing Atrial Fibrosis in Streptozotocin-Induced Diabetic Rat as Compared With Sulfonylurea.
    Hayami N; Sekiguchi A; Iwasaki YK; Murakawa Y; Yamashita T
    Int Heart J; 2016 May; 57(3):336-40. PubMed ID: 27149999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
    Bianchi R; Cervellini I; Porretta-Serapiglia C; Oggioni N; Burkey B; Ghezzi P; Cavaletti G; Lauria G
    J Pharmacol Exp Ther; 2012 Jan; 340(1):64-72. PubMed ID: 21984837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
    Maeda S; Yamagishi S; Matsui T; Nakashima S; Ojima A; Maeda S; Nishino Y; Ishibashi Y; Yoshida Y; Yamakawa R
    Ophthalmic Res; 2013; 50(4):221-6. PubMed ID: 24081217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The scientific evidence: vildagliptin and the benefits of islet enhancement.
    Mathieu C
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.
    Kosaraju J; Murthy V; Khatwal RB; Dubala A; Chinni S; Muthureddy Nataraj SK; Basavan D
    J Pharm Pharmacol; 2013 Dec; 65(12):1773-84. PubMed ID: 24117480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening.
    Srinivasan K; Viswanad B; Asrat L; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Oct; 52(4):313-20. PubMed ID: 15979893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Forst T; Dworak M; Berndt-Zipfel C; Löffler A; Klamp I; Mitry M; Pfützner A
    Diabetes Obes Metab; 2013 Jun; 15(6):576-9. PubMed ID: 23384119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute assessment of an aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential.
    Muller CJ; Joubert E; de Beer D; Sanderson M; Malherbe CJ; Fey SJ; Louw J
    Phytomedicine; 2012 Dec; 20(1):32-9. PubMed ID: 23083813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
    Kothny W; Shao Q; Groop PH; Lukashevich V
    Diabetes Obes Metab; 2012 Nov; 14(11):1032-9. PubMed ID: 22690943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ameliorative effect of selenium yeast in combination with pioglitazone on diabetes outcomes in streptozotocin-induced.
    Zakaraya ZZ; AlTamimi L; Hailat M; Ahmad MN; Qinna NA; Ghanim BY; Saadh MJ; Al-Dmour N; Dayyih WA
    J Popul Ther Clin Pharmacol; 2022; 29(4):e202-e210. PubMed ID: 36579951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
    Wang X; Zhang D; Xu W; Liu H; Wang W
    Xenobiotica; 2010 Oct; 40(10):707-12. PubMed ID: 20735236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.